Cardima CE marks surgical ablation probe for atrial fibrillation
This article was originally published in Clinica
Executive Summary
Cardiology specialist Cardima has CE marked its surgical ablation probe for sale in Europe. The probe is part of the firm's surgical ablation system, which is used to treat atrial fibrillation. The system can be employed in open-chest surgery in combination with other procedures, or alone in less-invasive, closed-chest procedures. During the latter, Cardima's system allows cardiac surgeons to gain access to the heart via "two or three small ports in the chest". The system also treats both the left and right aortas, which Cardima (Fremont, California) believes is necessary for successful treatment. The system is already approved by the US FDA for the ablation of cardiac tissue.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.